We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Melanoma Test Offers Reassurance of Low Risk of Cancer Spread

By LabMedica International staff writers
Posted on 25 Jan 2022
Print article
Image: The High Capacity RNA-to-cDNA Kit is a streamlined reverse transcription kit designed for optimum performance with TaqMan Gene Expression Master Mix, Power SYBR Green PCR Master Mix, and other PCR enzymes (Photo courtesy of Thermo Fisher Scientific)
Image: The High Capacity RNA-to-cDNA Kit is a streamlined reverse transcription kit designed for optimum performance with TaqMan Gene Expression Master Mix, Power SYBR Green PCR Master Mix, and other PCR enzymes (Photo courtesy of Thermo Fisher Scientific)
Cutaneous melanoma is an aggressive form of skin cancer with an increasing worldwide incidence, particularly in the younger population. Although treatment for patients with metastatic melanoma has improved remarkably in the last decade, principally with targeted therapies and immune checkpoint modulators, there are still no consistently beneficial treatments for patients with metastatic disease.

AMBRA1 is a scaffold protein with key roles in autophagy, cell survival and proliferation. AMBRA1 promotes autophagy through initiation of autophagosome formation, and mitophagy-mediated clearance of damaged mitochondria. Melanoma cells can influence the tumor microenvironment through secretion of growth factors, including transforming growth factors α and β (TGF-α, TGF-β).

Clinical Scientists at Newcastle University (Newcastle, UK) and AMLo Biosciences Limited (Newcastle upon Tyne, UK) and their colleagues evaluated the potential contribution of melanoma paracrine transforming growth factor (TGF)-β signaling to the loss of AMBRA1 in the epidermis overlying the primary tumor and disruption of epidermal integrity. Immunohistochemistry was used to analyze AMBRA1 and TGF-β2 in a cohort of 109 AJCC all-stage melanomas, and TGF-β2 and claudin-1 in a cohort of 30 or 42 AJCC stage I melanomas, respectively, with known AMBRA1 and loricrin (AMLo) expression. Evidence of pre-ulceration was analyzed in a cohort of 42 melanomas, with TGF-β2 signaling evaluated in primary keratinocytes.

The investigators performed semiquantitative immunohistochemistry for or AMBRA1, TGF-β2, TGF-β3, claudin-1 or AMLo expression. Claudin-1 expression was quantified by H-score using Aperio ImageScope (Leica Biosystems, Nussloch Germany). Western blotting was generated and visualized using enhanced chemiluminescence (Bio-Rad, Watford, UK). Total RNA was isolated from cell pellets and reverse transcribed using an AMV Reverse Transcriptase kit (Promega, Madison, WI, USA) or High Capacity Reverse Transcription Kit (Thermo Fisher Scientific, Waltham MA, USA).

The scientists reported that increased tumoral TGF-β2 was significantly associated with loss of peritumoral AMBRA1, ulceration, AMLo high-risk status and metastasis. TGF-β2 treatment of keratinocytes resulted in downregulation of AMBRA1, loricrin and claudin-1, while knockdown of AMBRA1 was associated with decreased expression of claudin-1 and increased proliferation of keratinocytes. Importantly, they showed loss of AMBRA1 in the peritumoral epidermis was associated with decreased claudin-1 expression, parakeratosis and cleft formation in the dermoepidermal junction.

Penny E. Lovat, PhD, Professor of Cellular Dermatology and senior author of the study, said, “Like mortar and bricks holding together a wall, AMBRA1, Loricrin and Claudin 1 are all proteins key to maintaining the integrity of the upper layer of the skin. When these proteins are lost gaps develop, like the mortar crumbling away in the wall. This allows the tumor to spread and ultimately ulcerate which we know is a process associated with higher risk tumors. Our new understanding of this biological mechanism underpins the test we have available.”

The authors concluded that their data suggested a paracrine mechanism whereby melanoma secretion of TGF-β2 causes peritumoral loss of AMBRA1 and reduced epidermal integrity facilitating erosion of the epidermis and tumor ulceration. Targeting TGF-β2 signaling may therefore represent a novel adjuvant treatment strategy for high-risk early-stage tumors with loss of epidermal AMBRA1. The study was published on January 13, 2022 in the British Journal of Dermatology.

Related Links:
Newcastle University
AMLo Biosciences Limited
Leica Biosystems
Bio-Rad
Promega
Thermo Fisher Scientific


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.